It has strong R&D capabilities. It invests nearly 10 million yuan in new product research and development every year, so as to research a batch, develop a batch, put a batch into production, reserve a batch, and have new products on the market every year. So far, more than 10 national-level new drugs and new drug imitations have been developed, including national first-class new drugs. These new drugs have high technological content, some products fill domestic gaps, the leading products have independent intellectual property rights, and the development and production of raw materials and preparations are supported. The company's leading product, Chuanliu (Aiplite Tablets), a national first-class new drug, is the first domestically effective drug for the treatment of benign prostatic hyperplasia. It obtained the national first-class new drug certificate in August 1999 and was approved by the Ministry of Science and Technology and the Ministry of Science and Technology in February 2001. The Ministry of Finance, the State Planning Commission, and the State Economic and Trade Commission rated it as an outstanding scientific and technological achievement in the Ninth Five-Year National Key Science and Technology Research Plan. In July 2004, it obtained the National Key New Product Certificate issued by the Ministry of Science and Technology, the Ministry of Commerce, the State Administration of Quality Supervision, and the State Environmental Protection Administration. The company has obtained the non-patented technology intellectual property rights of Aiplite since its establishment. It is the only manufacturer of this kind of drug and enjoys a 12-year exclusive production protection period. Aprelite and its tablets are a safe and effective drug for the treatment of prostatic hyperplasia. The drug can significantly improve the urinary symptoms of patients with prostatic hyperplasia, reduce prostate volume, and increase urine flow. The efficacy of Aprelite tablets is better than that of finasteride, and the efficacy can be obtained after two months of taking it. The drug has no serious adverse reactions, the incidence of adverse reactions related to the drug is low, and it is suitable for long-term use by the elderly. In October 2008, the company successfully developed Iprelate sustained-release preparations (tablets), which successively won the national invention patent and the silver medal at the 6th China International Invention Exhibition. The drug can maintain drug concentration, control drug release speed, maintain effective blood drug concentration in the body, improve efficacy, reduce the number of medication doses, and is easy to take and carry. The company's anti-allergic drug Mitil (terfenadine tablets) has successfully overcome the drowsiness reaction of traditional drugs. It is the first non-sedative anti-allergic drug in China. Terfenadine granules are suitable for those who have difficulty swallowing tablets and those who have difficulty swallowing tablets. Especially suitable for children. This product has won the Gold Award at the National High-Tech Expo and the Golden Bull Award for New Products in Jiangsu Province. Cetirizine Hydrochloride and Lishuang (Cetirizine Hydrochloride Tablets), Ebastine and Sudi (Ebastine Tablets) are the second and third generation products of non-sedating anti-allergic drugs. Sudi (Ebastine tablets) has strong, long-lasting and safe properties. In June 2005, it was recognized as a national key new product by the Ministry of Science and Technology, the Ministry of Commerce, the State Administration of Quality Supervision, and the State Environmental Protection Administration. The company's dicyclidine (felodipine tablets) is a new type of calcium ion antagonist that can selectively relax arterioles, improve heart and kidney function, and is widely adapted to the treatment needs of various patients with hypertension. In December 2008, it was recognized as a high-tech product by the Jiangsu Provincial Department of Science and Technology. Zhengzhi (Simvastatin Tablets) is suitable for hypercholesterolemia and coronary heart disease. Its superior safety profile is suitable for long-term use. The danazol capsules produced by the company are the first choice drug for the treatment of endometriosis to fill the domestic gap. It has won the Golden Bull Award for New Products in Jiangsu Province and the gold medal in the National All Disease Killer Competition; danazol suppositories have changed the route of administration. It acts directly on the diseased area and has a rapid onset of action. The daily dosage is only 1/12 of that of capsules and has minimal adverse reactions. It is a new dosage form of this product. The company produces a compound preparation consisting of metformin hydrochloride and gliclazide. The two drugs have complementary mechanisms of action and the dosage is lower than when the two drugs are used alone. Therefore, side effects are greatly reduced, which is beneficial to controlling blood sugar levels in diabetic patients. The balofloxacin tablets produced by the company have strong antibacterial activity. The in vitro antibacterial activity is 2 to 24 times that of ciprofloxacin and ofloxacin. The activity of staphylococci sensitive to fluoroquinolone drugs is higher than that of ofloxacin and ciprofloxacin. Balofloxacin is 4 times more powerful than other antibiotics; balofloxacin is well tolerated, has few and mild adverse reactions, and has no effect on the central nervous system. The company's Dicyclodine (sertraline hydrochloride capsules) is used to treat depression, including depression accompanied by anxiety, with or without a history of mania, and also used to treat obsessive-compulsive disorder. The drug has high potency, 200 times that of amitriptyline and 36 times that of fluoxetine. It is safe and has almost no clinical antidepressant effect after being metabolized into norsertraline in the body.